S. O. Litvinov

S. O. Litvinov

Auto-generated profile, based on publicly available information

S. O. Litvinov

Pirogov Russian National Research Medical University (Pirogov Medical University)

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in Urology Herald
Verified
Journal Article
Closed access
EAE. A. Alekberov
E. A. Alekberov
SPS. A. Pulbere
S. A. Pulbere
MIM. M. Iritsyan
M. M. Iritsyan
NKN. D. Korochkin
N. D. Korochkin
GBG. V. Badakva
G. V. Badakva
SKS. V. Kotov
S. V. Kotov
Introduction . Lichen sclerosus (LS) is one of the common aetiological factors underlying phimosis. However, this cause frequently remains unrecognised in routine clinical practice. Clear, evidence‑based algorithms for the management of phimosis complicated by LS are currently lacking or fail to achieve satisfactory effectiveness. Objective . To evaluate the efficacy and safety of topical glucocorticosteroid (GCS) therapy after circumcision in men with histologically confirmed LS. Materials & methods . This prospective randomised study included 132 adult men who underwent circumcision for phimosis between 2023 and 2025. Following histopathological assessment of the preputial specimens, we performed a comparative analysis of patients with and without LS. The severity of genital skin involvement, including histological parameters, as well as selected somatic comorbidities and clinical indices, was assessed. LS-patients were randomised into two groups: group A (study group) comprised 13 patients who received postoperative topical clobetasol propionate 0.05% under regular specialist follow‑up, whereas group B (control group) included 14 patients who were followed up without topical GCS therapy. Results . LS was identified as the aetiological factor of phimosis in 20.45% (27/132) of cases. The effectiveness of the combined approach in the study group reached 100%, while in the control group the corresponding rate was 78.4%. Conclusion. LS is diagnosed in approximately one in five patients undergoing circumcision for phimosis. In the presence of LS affecting the prepuce and glans penis, a combined strategy consisting of circumcision followed by adjuvant topical GCS therapy appears to be a curative option for this patient population.

5 April 2026 in Urology Herald
Verified
Journal Article
Closed access
AMA. A. Mantsov
A. A. Mantsov
AKA. A. Klimenko
A. A. Klimenko
EAE. M. Alekberov
E. M. Alekberov
SLS. O. Litvinov
S. O. Litvinov
SBS. V. Belomytsev
S. V. Belomytsev
SKS. V. Kotov
S. V. Kotov
Introduction . Urethral stricture is a common urological condition that substantially impairs patients' quality of life. Historically, restoration of spontaneous voiding has been considered the primary success criterion for stricture management. However, contemporary urethroplasty decision-making rarely accounts for potential postoperative sexual dysfunctions in men, including ejaculatory and erectile disorders, penile curvature and shortening, reduced genital sensation, and impaired glans blood supply. Objective . To identify risk factors for ejaculatory dysfunction following urethroplasty and quantify their impact. Materials & methods . We evaluated 74 patients with urethral strictures treated surgically from 2015 to 2024. Ejaculatory function was assessed using the Male Sexual Health Questionnaire — Ejaculatory Dysfunction Short Form (MSHQ-EjD SF) preoperatively and at 12 months postoperatively. Results . At 12 months, patients aged ≥ 60 years exhibited statistically significant declines in ejaculation achievement, force, and ejaculate volume. Similar deteriorations occurred in patients with hypertension and diabetes mellitus (across all three parameters) and coronary artery disease (ejaculation force and volume only). Conversely, patients undergoing urethroplasty without corpus spongiosum transection showed preserved ejaculation parameters. Conclusion . Urethroplasty may induce de novo ejaculatory dysfunction. Principal risk factors include advanced age (≥ 60 years), comorbidities (hypertension, diabetes mellitus, coronary artery disease), and surgical transection of the corpus spongiosum.